Logo image of ALMS

ALUMIS INC (ALMS) Stock Fundamental Analysis

NASDAQ:ALMS - Nasdaq - US0223071020 - Common Stock - Currency: USD

5  -0.07 (-1.38%)

After market: 4.94 -0.06 (-1.2%)

Fundamental Rating

2

ALMS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 197 industry peers in the Pharmaceuticals industry. ALMS has a great financial health rating, but its profitability evaluates not so good. ALMS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ALMS had negative earnings in the past year.
In the past year ALMS has reported a negative cash flow from operations.
ALMS Yearly Net Income VS EBIT VS OCF VS FCFALMS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -100M -200M -300M

1.2 Ratios

The Return On Assets of ALMS (-86.29%) is worse than 73.74% of its industry peers.
The Return On Equity of ALMS (-113.12%) is worse than 60.10% of its industry peers.
Industry RankSector Rank
ROA -86.29%
ROE -113.12%
ROIC N/A
ROA(3y)-120.91%
ROA(5y)N/A
ROE(3y)-222.13%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALMS Yearly ROA, ROE, ROICALMS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ALMS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALMS Yearly Profit, Operating, Gross MarginsALMS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

ALMS has more shares outstanding than it did 1 year ago.
ALMS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ALMS Yearly Shares OutstandingALMS Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M 40M 50M
ALMS Yearly Total Debt VS Total AssetsALMS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 100M 200M 300M

2.2 Solvency

ALMS has an Altman-Z score of -2.70. This is a bad value and indicates that ALMS is not financially healthy and even has some risk of bankruptcy.
ALMS has a Altman-Z score (-2.70) which is in line with its industry peers.
There is no outstanding debt for ALMS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.7
ROIC/WACCN/A
WACCN/A
ALMS Yearly LT Debt VS Equity VS FCFALMS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 100M -100M 200M -200M

2.3 Liquidity

A Current Ratio of 6.01 indicates that ALMS has no problem at all paying its short term obligations.
With a decent Current ratio value of 6.01, ALMS is doing good in the industry, outperforming 75.25% of the companies in the same industry.
A Quick Ratio of 6.01 indicates that ALMS has no problem at all paying its short term obligations.
With a decent Quick ratio value of 6.01, ALMS is doing good in the industry, outperforming 75.25% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.01
Quick Ratio 6.01
ALMS Yearly Current Assets VS Current LiabilitesALMS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for ALMS have decreased strongly by -80.89% in the last year.
EPS 1Y (TTM)-80.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.74%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ALMS will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.80% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y52.17%
EPS Next 2Y26.75%
EPS Next 3Y15.8%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALMS Yearly Revenue VS EstimatesALMS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2M 4M 6M 8M 10M
ALMS Yearly EPS VS EstimatesALMS Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 -2 -4 -6 -8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ALMS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALMS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALMS Price Earnings VS Forward Price EarningsALMS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALMS Per share dataALMS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

ALMS's earnings are expected to grow with 15.80% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.75%
EPS Next 3Y15.8%

More info and screens

0

5. Dividend

5.1 Amount

ALMS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALUMIS INC

NASDAQ:ALMS (4/17/2025, 8:01:40 PM)

After market: 4.94 -0.06 (-1.2%)

5

-0.07 (-1.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-19 2025-03-19/amc
Earnings (Next)N/A N/A
Inst Owners67.25%
Inst Owner Change0.01%
Ins Owners1.2%
Ins Owner Change0%
Market Cap272.05M
Analysts87.27
Price Target22.19 (343.8%)
Short Float %8.67%
Short Ratio14.89
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)40.65%
Min EPS beat(2)-2.48%
Max EPS beat(2)83.78%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.4%
PT rev (3m)-27.5%
EPS NQ rev (1m)-27.84%
EPS NQ rev (3m)-18.03%
EPS NY rev (1m)-4.27%
EPS NY rev (3m)15.62%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.05
P/tB 1.05
EV/EBITDA N/A
EPS(TTM)-5.5
EYN/A
EPS(NY)-4.23
Fwd EYN/A
FCF(TTM)-4.72
FCFYN/A
OCF(TTM)-4.69
OCFYN/A
SpS0
BVpS4.78
TBVpS4.78
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -86.29%
ROE -113.12%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-120.91%
ROA(5y)N/A
ROE(3y)-222.13%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 54.95%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.01
Quick Ratio 6.01
Altman-Z -2.7
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)455.91%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-80.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.74%
EPS Next Y52.17%
EPS Next 2Y26.75%
EPS Next 3Y15.8%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-90.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-0.37%
EBIT Next 3Y4.34%
EBIT Next 5YN/A
FCF growth 1Y-90.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-96.25%
OCF growth 3YN/A
OCF growth 5YN/A